CROWN BIOSCIENCE

Biomarkers of Response

Discover and validate novel oncology biomarkers

A JSR Life Sciences Company

Access 2,500 Solid Tumor PDX (patient-derived xenograft) *in vivo* models to identify biomarkers of response.

Profile, identify, and confirm PD, surrogate, and predictive biomarkers, and annotated Solid Tumor PDX Models.

- Large, diverse collection of 2,500 PDX models from US, European, and Asian populations covering >30 cancer types.

- Curated, online, searchable PDX Model Database of:
  - Phenotypic and genotypic data
  - Patient information
  - Growth curves
  - Standard of care treatment data

- Constantly growing panels of PDX with patient-relevant mutations

- Unique models for targeted therapy e.g., RET, ALK, EGFR

- PD biomarker studies by IHC to discover pharmacodynamic response

Differentiate between responders and non-responders in a patient population

Discover pharmacology response by IHC from *in vivo* efficacy studies

Validate targets by screening population response to drug candidates

T-c-Met, p-c-Met, and HGF in 20 lung Hu**Prime** models

Get in touch

Sales
US: +1 858 622 2900   busdev@crownbio.com
UK: +44 153 023 4871   www.crownbio.com